Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2008

Jänne Pasi A

Abstract excerpt

For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi- dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, into clinical practice was promising. Treatment with either of these agents is associated with an objective response in 10-20% of patients. Subsequent studies have shown that patients responsive to gefitinib/erlotinib have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Gene Expression Regulation, Neoplastic

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 18513582
DOI: 10.1016/S0169-5002(08)70099-0

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.PMID 18513582Read ↗

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Semantic proximity Read ↗

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.Semantic proximity Read ↗

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Semantic proximity Read ↗

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.Semantic proximity Read ↗

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.Semantic proximity Read ↗

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Semantic proximity Read ↗

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.Semantic proximity Read ↗

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.Semantic proximity Read ↗

Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.Semantic proximity Read ↗

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Semantic proximity Read ↗

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

EGFR T790M resistance mutation in non small-cell lung carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.